Login to Your Account

Financings Roundup

GTx to Raise $47.5M to Develop Cancer Drugs

By Mari Serebrov

Friday, June 24, 2011
With its sights set on pushing two cancer candidates through the pipeline, GTx Inc. is looking to a $47.5 million public offering to fund Phase III development of Ostarine and Phase II trials for Capesaris.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription